MetaCap

Humana (HUM) vs Natera (NTRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Humana (HUM) has outperformed Natera (NTRA) over the past year, gaining 71.7% versus a gain of 18.5%. Over five years, NTRA leads with a +188.8% price change compared with -9.0% for HUM. Humana is the larger company by market cap ($46.84 billion vs $39.64 billion), about 1.2 times the size, while Natera is growing revenue faster (+35.9% vs +10.1%).

Humana pays a dividend yielding 0.91%, while Natera does not currently pay one. Humana converts more of its revenue into profit, with a net margin of 0.9% versus -9.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HUM+71.73%NTRA+18.54%
+110%+38%-34%
Nov 21, 20251 yearNov 20, 2026
HUM-10.32%NTRA+164.97%
+320%+117%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HUM versus NTRA key metrics
MetricHUMNTRA
Share price$390.00$273.40
Market cap$46.84B$39.64B
1-day change+2.63%-5.70%
YTD return+52.27%+19.34%
1-year return+71.73%+18.54%
5-year return-8.98%+188.82%
P/E ratio (TTM)38.05—
Forward P/E21.06—
EPS (TTM)$10.25$-1.12
Dividend yield0.91%0.00%
Annual dividend$3.54$0.00
Revenue (latest FY)$129.66B$2.31B
Revenue growth (YoY)+10.11%+35.90%
Net income (latest FY)$1.19B$-208.16M
Operating margin2.09%-13.44%
Net margin0.92%-9.03%
52-week high$462.87$437.41
52-week low$163.11$181.00
Distance from 52-week high-15.74%-37.50%
Analyst consensusbuystrong_buy
Avg. price target upside+30.98%+50.06%
Average volume1.46M1.77M
Shares outstanding120.10M145.00M
Employees67,0606,135
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HUM has outperformed NTRA by 53.2 percentage points over the past year.
  • Humana is more profitable, keeping 0.9 cents of every revenue dollar as net income versus -9.0 cents for Natera.
  • Natera grew revenue faster in its latest fiscal year (+35.90% vs +10.11%).

About Humana

HUM stock →

Humana Inc. provides medical and specialty insurance products in the United States.

Health Care · Medical Specialities · 67,060 employees

About Natera

NTRA stock →

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.

Health Care · Medical Specialities · 6,135 employees

HUM vs NTRA FAQ

Which is bigger, Humana or Natera?

Humana (HUM) is larger, with a market capitalization of $46.84B compared with $39.64B for Natera (NTRA).

Which stock has performed better over the past year, HUM or NTRA?

HUM returned +71.73% over the past 12 months, compared with +18.54% for NTRA (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Humana or Natera?

Humana pays a dividend yielding 0.91%, while Natera does not currently pay a regular dividend.

Are Humana and Natera in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons